BACKGROUND: There are limited data concerning the relationships between changes in adipocytokines and cardiovascular disease (CVD) risk factors. OBJECTIVE: To examine the longitudinal associations between leptin, adiponectin, resistin and ghrelin levels and CVD risk factor levels in women at midlife. DESIGN: Prospective, observational study. SUBJECTS AND MEASUREMENTS: Leptin, adiponectin, resistin, ghrelin levels and CVD risk factors were measured in specimens collected from 40 women at 3 points in time corresponding to the pre-, peri- and postmenopause stages of their natural menopause transition. RESULTS: In longitudinal analyses adjusted for CVD risk factors and leptin at the previous menopausal stage, aging, education, smoking and physical activity, greater increases in leptin over the menopause transition were associated with greater decreases in high-density lipoprotein cholesterol (HDL-c) and greater increases in diastolic blood pressure, glucose, insulin and insulin resistance (all P < 0.05). Larger decreases in adiponectin over the menopause transition were associated with greater increases in systolic blood pressure, insulin and insulin resistance and with greater decreases in HDL-c. Greater increases in ghrelin levels over the menopausal transition were associated with greater low-density lipoprotein cholesterol increases (P = 0.014). Resistin was not associated with CVD risk factor changes. CONCLUSION: There were significant adverse associations of adipocytokines and ghrelin with multiple CVD risk factor changes in women across midlife. Given that this time period is dynamic for CVD risk, these data underscore the need for additional prospective studies.
BACKGROUND: There are limited data concerning the relationships between changes in adipocytokines and cardiovascular disease (CVD) risk factors. OBJECTIVE: To examine the longitudinal associations between leptin, adiponectin, resistin and ghrelin levels and CVD risk factor levels in women at midlife. DESIGN: Prospective, observational study. SUBJECTS AND MEASUREMENTS: Leptin, adiponectin, resistin, ghrelin levels and CVD risk factors were measured in specimens collected from 40 women at 3 points in time corresponding to the pre-, peri- and postmenopause stages of their natural menopause transition. RESULTS: In longitudinal analyses adjusted for CVD risk factors and leptin at the previous menopausal stage, aging, education, smoking and physical activity, greater increases in leptin over the menopause transition were associated with greater decreases in high-density lipoprotein cholesterol (HDL-c) and greater increases in diastolic blood pressure, glucose, insulin and insulin resistance (all P < 0.05). Larger decreases in adiponectin over the menopause transition were associated with greater increases in systolic blood pressure, insulin and insulin resistance and with greater decreases in HDL-c. Greater increases in ghrelin levels over the menopausal transition were associated with greater low-density lipoprotein cholesterol increases (P = 0.014). Resistin was not associated with CVD risk factor changes. CONCLUSION: There were significant adverse associations of adipocytokines and ghrelin with multiple CVD risk factor changes in women across midlife. Given that this time period is dynamic for CVD risk, these data underscore the need for additional prospective studies.
Authors: J F Sallis; W L Haskell; P D Wood; S P Fortmann; T Rogers; S N Blair; R S Paffenbarger Journal: Am J Epidemiol Date: 1985-01 Impact factor: 4.897
Authors: Tobias Pischon; Cynthia J Girman; Gokhan S Hotamisligil; Nader Rifai; Frank B Hu; Eric B Rimm Journal: JAMA Date: 2004-04-14 Impact factor: 56.272
Authors: Rachel P Wildman; Laura L Schott; Sarah Brockwell; Lewis H Kuller; Kim Sutton-Tyrrell Journal: J Am Coll Cardiol Date: 2004-08-04 Impact factor: 24.094
Authors: Alexandra D Ogorodnikova; Sylvia Wassertheil-Smoller; Peter Mancuso; MaryFran R Sowers; Swapnil N Rajpathak; Matthew A Allison; Alison E Baird; Beatriz Rodriguez; Rachel P Wildman Journal: Stroke Date: 2010-05-27 Impact factor: 7.914
Authors: Daniel R Christie; Jan Grant; Betty E Darnell; Victoria R Chapman; Amalia Gastaldelli; Cynthia K Sites Journal: Am J Obstet Gynecol Date: 2010-05-01 Impact factor: 8.661
Authors: Roksana Karim; Frank Z Stanczyk; Roberta D Brinton; Jamaica Rettberg; Howard N Hodis; Wendy J Mack Journal: J Clin Endocrinol Metab Date: 2014-11-18 Impact factor: 5.958
Authors: Robert C Kaplan; Garrett Strizich; Chino Aneke-Nash; Clara Dominguez-Islas; Petra Bužková; Howard Strickler; Thomas Rohan; Michael Pollak; Lewis Kuller; Jorge R Kizer; Anne Cappola; Christopher I Li; Bruce M Psaty; Anne Newman Journal: J Clin Endocrinol Metab Date: 2017-01-01 Impact factor: 5.958
Authors: Erik Ingelsson; Martin G Larson; Xiaoyan Yin; Thomas J Wang; James B Meigs; Izabella Lipinska; Emelia J Benjamin; John F Keaney; Ramachandran S Vasan Journal: J Clin Endocrinol Metab Date: 2008-05-20 Impact factor: 5.958
Authors: Carrie A Karvonen-Gutierrez; Huiyong Zheng; Peter Mancuso; Siobán D Harlow Journal: J Gerontol A Biol Sci Med Sci Date: 2015-08-24 Impact factor: 6.053
Authors: Christine G Lee; Molly C Carr; Susan J Murdoch; Ellen Mitchell; Nancy F Woods; Mark H Wener; Wayne L Chandler; Edward J Boyko; John D Brunzell Journal: J Clin Endocrinol Metab Date: 2009-01-06 Impact factor: 5.958
Authors: Maryfran Sowers; Carrie A Karvonen-Gutierrez; Riann Palmieri-Smith; Jon A Jacobson; Yebin Jiang; James A Ashton-Miller Journal: Arthritis Rheum Date: 2009-10-15